Intravesical chemotherapy of high-grade bladder cancer with HTI-286, a synthetic analogue of the marine sponge product hemiasterlin

Clinical Cancer Research

Volumn 14, Issue 5, 2008, Pages 1510-1518

  Hadaschik, Boris A ^a   Adomat, Hans ^a   Fazli, Ladan ^a   Fradet, Yves ^b   Andersen, Raymond J ^a   Gleave, Martin E ^a   So, Alan I ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Department of Urologic Sciences ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMIASTERLIN; LUCIFERASE; MITOMYCIN C; TALTOBULIN; TRIPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOAVAILABILITY; BIOLOGY; BIOLUMINESCENCE; BLADDER CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG URINE LEVEL; EMBRYO; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUMINESCENCE; MICE; MICE, NUDE; MITOMYCIN; OLIGOPEPTIDES; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 40949090477     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4475     Document Type: Article

References (46)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Clark PE. Bladder cancer. Curr Opin Oncol 2007;19:241-7.
3. Dalbagni G. The management of superficial bladder cancer. Nat Clin Pract Urol 2007;4:254-60.
4. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
5. Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96-100.
6. Sylvester RJ, van der MA, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964-70.
7. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4:253-65.
8. McKiernan JM, Masson P, Murphy AM, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol 2006;24:3075-80.
9. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.
10. Nieman JA, Coleman JE, Wallace DJ, et al. Synthesis and antimitotic/cytotoxic activity of hemiasterlin analogues. J Nat Prod 2003;66:183-99.
11. Zask A, Birnberg G, Cheung K, et al. Synthesis and biological activity of analogues of the antimicrotubule agent N,β,β-trimethyl- L-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbu t-2-enyl]-N(1),3-dimethyl-L-valinamide (HTI-286). J Med Chem 2004;47:4774-86.
12. Nunes M, Kaplan J, Wooters J, et al. Two photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label α-tubulin. Biochemistry 2005;44:6844-57.
13. Ravi M, Zask A, Rush TS III. Structure-based identification of the binding site for the hemiasterlin analogue HTI-286 on tubulin. Biochemistry 2005;44:15871-9.
14. Krishnamurthy G, Cheng W, Lo MC, et al. Biophysical characterization of the interactions of HTI-286 with tubulin heterodimer and microtubules. Biochemistry 2003;42:13484-95.
15. Anderson HJ, Coleman JE, Andersen RJ, Roberge M. Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation. Cancer Chemother Pharmacol 1997;39:223-6.
16. Loganzo F, Discafani CM, Annable T, et al. HTI-286, a synthetic analogue of the tripeptide hemiasterlin, is a potent antimicrotubule agent that circumvents P-glycoprotein-mediated resistance in vitro and in vivo. Cancer Res 2003;63:1838-45.
17. Loganzo F, Hari M , Annable T, et al. Cells resistant to HTI-286 do not overexpress P-glycoprotein but have reduced drug accumulation and a point mutation in α-tubulin. Mol Cancer Ther 2004;3:1319-27.
18. Lin CW, Lin JC, Prout GR, Jr. Establishment and characterization of four human bladder tumor cell lines and sublines with different degrees of malignancy. Cancer Res 1985;45:5070-9.
19. Tachibana M, Miyakawa A, Uchida A, et al. Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder. Br J Cancer 1997;75:1489-96.
20. Arumugam T, Ramachandran V, Logsdon CD. Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models. J Natl Cancer Inst 2006;98:1806-18.
21. Zellweger T, Chi K, Miyake H, et al. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res 2002;8:3276-84.
22. Darzynkiewicz Z, Huang X, Okafuji M, King MA. Cytometric methods to detect apoptosis. Methods Cell Biol 2004;75:307-41.
23. Ahlering TE, Dubeau L, Jones PA. A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res 1987;47:6660-5.
24. Watanabe T, Shinohara N, Sazawa A, et al. An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 2000;7:1575-80.
25. Wieling J. LC-MS-MS experiences with internal standards. Chromatographia 2002;55:S107-113.
26. Crallan RA, Georgopoulos NT, Southgate J. Experimental-models of human bladder carcinogenesis. Carcinogenesis 2006;27:374-81.
27. Vashist YK, Tiffon C, Stoupis C, Redaelli CA. Inhibition of hepatic tumor cell proliferation in vitro and tumor growth in vivo by taltobulin, a synthetic analogue of the tripeptide hemiasterlin. World J Gastroenterol 2006;12:6771-8.
28. Schmittgen TD, Wientjes MG, Badalament RA, Au JL. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 1991;51:3849-56.
29. Watts PL, Plumb JA, Courtney JM, Scott R. Sensitivity of cell lines to mitomycin C. Br J Urol 1996;77:363-6.
30. Hadaschik BA, Black PC, Sea JC, et al. A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging. BJU Int 2007;100:1377-84.
31. Au JL, Kalns J, Gan Y, Wientjes MG. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother Pharmacol 1997;41:69-74.
32. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin Cancer Res 2004;10:7677-84.
33. Ayral-Kaloustian S, Zask A. Taltobulin. Drugs Fut 2005;30:254-60.
34. Song D, Wientjes MG, Au JL. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother Pharmacol 1997;40:285-92.
35. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
36. Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res 1999;59:3512-7.
37. Smakman N, Schaap N, Snijckers CM, Borel Rinkes IH, Kranenburg O. NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation. Urology 2005;66:434-40.
38. Nogawa M, Yuasa T, Kimura S, et al. Intravesical administration of small interfering RNA targeting PLK-1successfully prevents the growth of bladder cancer. J Clin Invest 2005;115:978-85.
39. Karam JA, Fan J, Stanfield J, et al. The use of histone deacetylase inhibitor FK228 and DNA hypomethylation agent 5-azacytidine in human bladder cancer therapy. Int J Cancer 2007;120:1795-802.
40. Ramesh N, Ge Y, Ennist DL, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 2006;12:305-13.
41. Dang LH, Bettegowda C, Agrawal N, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-37.
42. Crawford ED. Intravesical therapy for superficial cancer: need for more options. J Clin Oncol 2002;20:3185-6.
43. Ratain MJ, Undevia S, Janisch L, et al. Phase 1 and pharmacological study of HTI-286, a novel antimicrotubule agent: correlation of neutropenia with time above a threshold serum concentration. Proc Am Soc Clin Oncol 2003;22:Abstract 516.
44. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
45. See WA, Xia Q. Regional chemotherapy for bladder neoplasms using continuous intravesical infusion of doxorubicin: impact of concomitant administration of dimethyl sulfoxide on drug absorption and antitumor activity. J Natl Cancer Inst 1992;84:510-5.
46. Chen D, Song D, Wientjes MG, Au JL. Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. Clin Cancer Res 2003;9:363-9.